• Issue

    The Prostate: Volume 82, Issue 15

    1413-1480
    November 1, 2022
Previous Issue|Next Issue
Export Citation(s)Download PDF(s)

ISSUE INFORMATION

Free Access

Issue Information

  • Page: 1413
  • First Published: 21 September 2022

ORIGINAL ARTICLES

Optimization of prostate cancer patient lymph node staging via the integration of neutrophil–lymphocyte ratios, platelet–lymphocyte ratios, and 68Ga-PSMA-PET-derived SUVmax values

Yinzhao Wang MD,  Yongxiang Tang MD,  Xiaomei Gao MD,  Yu Gan MD,  Shuo Hu MD,  Min-Feng Chen MD,  Yi Cai MD, 
  • Pages: 1415-1421
  • First Published: 21 July 2022
Open Access

Prostate tumor RON receptor signaling mediates macrophage recruitment to drive androgen deprivation therapy resistance through Gas6-mediated Axl and RON signaling

Nicholas E. Brown PhD,  Angelle Jones BS,  Brian G. Hunt BS,  Susan E. Waltz PhD, 
  • Pages: 1422-1437
  • First Published: 21 July 2022

Better preservation of erectile function in localized prostate cancer patients with modern proton therapy: Is it cost-effective?

Guo Li MD,  Yun-Fei Xia MD,  Yi-Xiang Huang PhD,  Deniz Okat PhD,  Bo Qiu MD,  Jerome Doyen PhD,  Pierre-Yves Bondiau MD,  Karen Benezery MD,  Jin Gao MD,  Chao-Nan Qian MD, PhD, 
  • Pages: 1438-1446
  • First Published: 01 August 2022

Using health insurance claims data to assess long-term disease progression in a prostate cancer cohort

Saira Khan PhD, MPH,  Sanah Vohra PhD, MPH,  Laura Farnan PhD,  Shekinah N. C. Elmore MD,  Khadijah Toumbou MA,  Madhav K. C. PhD, MPH,  Elizabeth T. H. Fontham DrPH,  Edward S. Peters DMD, SM, ScD,  James L. Mohler MD,  Jeannette T. Bensen PhD, MS, 
  • Pages: 1447-1455
  • First Published: 26 July 2022

Prognostic role of pan-immune-inflammation value in patients with metastatic castration-resistant prostate cancer treated with androgen receptor-signaling inhibitors

Satı Coşkun Yazgan MD,  Emre Yekedüz MD,  Güngör Utkan MD,  Yüksel Ürün MD, 
  • Pages: 1456-1461
  • First Published: 28 July 2022

Comparison of 68Ga-PSMA PET/CT and mp-MRI in regard to local staging for prostate cancer with histopathological results: A retrospective study

Taha Ucar MD,  Nesrin Gunduz MD,  Emre Demirci MD,  Meftun Culpan MD,  Humeyra Gunel MD,  Gozde Kir MD,  Ramazan Gokhan Atis MD,  Asif Yildirim MD, 
  • Pages: 1462-1468
  • First Published: 01 August 2022

New strategy for the identification of prostate cancer: The combination of Proclarix and the prostate health index

Daniela Terracciano PhD,  Evelina La Civita PhD,  Alcibiade Athanasiou MSc,  Antonietta Liotti PhD,  Mariano Fiorenza MSc,  Michele Cennamo MD,  Felice Crocetto MD,  Pierre Tennstedt PhD,  Ralph Schiess PhD,  Alexander Haese MD,  Matteo Ferro MD,  Thomas Steuber MD, 
  • Pages: 1469-1476
  • First Published: 16 August 2022

RAPID COMMUNICATION

Open Access

Association between duration of gonadotrophin-releasing hormone agonist use and cardiovascular risks: A population-based competing-risk analysis

Jeffrey S. K. Chan MBChB,  Pias Tang MBBS,  Jeremy M. Ho Hui,  Yan H. A. Lee,  Edward C. Dee MD,  Kenrick Ng MA MRCP PhD,  Kang Liu MD,  Gary Tse MD, PhD, FRCP, FFPH, FRCPath,  Chi Fai Ng MBChB MD FRCSEd FCSHK FRCSEd (Urol) FHKAM (Surgery), 
  • Pages: 1477-1480
  • First Published: 01 August 2022